Burden, Access and Disparities in Kidney Disease

Deidra C. Crews,1,2,3 Aminu K. Bello,4 and Gamal Saadi,5

1Division of Nephrology, Department of Medicine, Johns Hopkins University School of Medicine, Baltimore, Maryland USA;  
2Welch Center for Prevention, Epidemiology and Clinical Research, Johns Hopkins Medical Institutions, Baltimore, Maryland USA;  
3Johns Hopkins Center for Health Equity, Johns Hopkins Medical Institutions, Baltimore, Maryland USA;  
4Division of Nephrology & Transplant Immunology, Department of Medicine, University of Alberta, Edmonton, Canada;  
5Nephrology Unit, Department of Internal Medicine, Faculty of Medicine, Cairo University, Giza, Egypt

ABSTRACT
Kidney disease is a global public health problem, affecting over 750 million persons worldwide. The burden of kidney disease varies substantially across the world, as does its detection and treatment. In many settings, rates of kidney disease and the provision of its care are defined by socio-economic, cultural, and political factors leading to significant disparities. World Kidney Day 2019 offers an opportunity to raise awareness of kidney disease and highlight disparities in its burden and current state of global capacity for prevention and management. Here, we highlight that many countries still lack access to basic diagnostics, a trained nephrology workforce, universal access to primary health care, and renal replacement therapies. We point to the need for strengthening basic infrastructure for kidney care services for early detection and management of acute kidney injury and chronic kidney disease across all countries and advocate for more pragmatic approaches to providing renal replacement therapies. Achieving universal health coverage worldwide by 2030 is one of the World Health Organization’s Sustainable Development Goals. While universal health coverage may not include all elements of kidney care in all countries, understanding what is feasible and important for a country or region with a focus on reducing the burden and consequences of kidney disease would be an important step towards achieving kidney health equity.

INTRODUCTION
Kidney disease is a global public health problem, affecting over 750 million persons worldwide1. The burden of kidney disease varies substantially across the world, as does its detection and treatment. While the magnitude and impact of kidney disease is better defined in developed countries, emerging evidence suggests developing countries have similar or even greater kidney disease burden2. In many settings, rates of kidney disease and the provision of its care are defined by socioeconomic, cultural, and political factors leading to significant disparities in disease burden, even in developed countries3. These disparities exist across the spectrum of kidney disease—from preventive efforts to curb development of acute kidney injury (AKI) or chronic kidney disease (CKD), to screening for kidney disease among persons at high risk, to access to subspecialty care and treatment of kidney failure with renal replacement therapy (RRT). World Kidney Day 2019 offers an opportunity to raise awareness of kidney disease and highlight disparities in its burden.

Corresponding author: Deidra C. Crews, Johns Hopkins University School of Medicine, 301 Mason F. Lord Drive, Suite 2500 Baltimore, Maryland 21224, USA. E-mail: dcrews1@jhmi.edu; Tel: (410) 550-2820
and current state of global capacity for prevention and management. In this editorial, we highlight these disparities and emphasize the role of public policies and organizational structures in addressing them. We outline opportunities to improve our understanding of disparities in kidney disease, how best they can be addressed, and how to streamline efforts towards achieving kidney health equity across the globe.

BURDEN OF KIDNEY DISEASE

Availability of data reflecting the full burden of kidney disease varies substantially due to limited or inconsistent data collection and surveillance practices worldwide (Table 1) 

Table 1: World Bank Country Group Chronic Kidney Disease Gaps

<table>
<thead>
<tr>
<th>CKD Care</th>
<th>Low-Income Countries (%)</th>
<th>Lower-Middle-Income Countries (%)</th>
<th>Upper Middle-Income Countries (%)</th>
<th>High-Income Countries (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>Governmental recognition of CKD as a health priority</td>
<td>59</td>
<td>50</td>
<td>17</td>
<td>29</td>
</tr>
<tr>
<td>Government funds all aspects of CKD care</td>
<td>13</td>
<td>21</td>
<td>40</td>
<td>53</td>
</tr>
<tr>
<td>Availability of CKD management and referral guidelines (international, national, or regional)</td>
<td>46</td>
<td>73</td>
<td>83</td>
<td>97</td>
</tr>
<tr>
<td>Existence of current CKD detection programs</td>
<td>6</td>
<td>24</td>
<td>24</td>
<td>32</td>
</tr>
<tr>
<td>Availability of dialysis registries</td>
<td>24</td>
<td>48</td>
<td>72</td>
<td>89</td>
</tr>
<tr>
<td>Availability of academic centers for renal clinical trial management</td>
<td>12</td>
<td>34</td>
<td>62</td>
<td>63</td>
</tr>
</tbody>
</table>

CKD: chronic kidney disease


and registries) is essential and requires substantial investment 

In addition to a need for functional surveillance systems, the global importance of kidney disease (including AKI and CKD) is yet to be widely acknowledged, making it a neglected disease on the global policy agenda. For instance, the World Health Organization (WHO) Global Action Plan for the Prevention and Control of Non-Communicable Diseases (NCDs) (2013) focuses on cardiovascular diseases, cancer, chronic respiratory diseases, and diabetes, but not kidney disease despite advocacy efforts by relevant stakeholders such as the International Society of Nephrology (ISN) and the International Federation of Kidney Foundations through activities like World Kidney Day. This is quite concerning as estimates from the Global Burden of Disease study in 2015 showed that around 1.2 million people were known to have died of CKD 7, and over 2 million people died in 2010 because they had no access to dialysis. It is estimated that another 1.7 million die from AKI on an annual basis 8,9. It is possible, therefore, that kidney disease may contribute towards high quality information on kidney disease burden and attendant consequences.
Hypertension is present in over 90% of individuals with advanced kidney disease \(^{18}\), yet racial/ethnic minorities and low-income persons with CKD living in high-income countries have poorer blood pressure control than their more socially advantaged counterparts \(^{21}\).

Lifestyle behaviors, including dietary patterns, are strongly influenced by socioeconomic status. In recent years, several healthful dietary patterns have been associated with favorable CKD outcomes \(^{22}\). Low-income individuals often face barriers to healthful eating which may increase their risk of kidney disease \(^{23-25}\). People of low socioeconomic status often experience food insecurity (limited access to affordable nutritious foods), which is a risk factor for CKD \(^{26}\) and progression to kidney failure \(^{27}\). In low-income countries, food insecurity may lead to undernutrition and starvation which has implications for both the individual, and in the case of women of child-bearing age, could lead to their children having low birth weight and related sequelae, including CKD \(^{28}\). Rates of undernourishment are as high as 35% or more in countries such as Haiti, Namibia, and Zambia \(^{29}\). However, in high-income countries, food insecurity is associated with overnutrition, and food insecure persons have increased risk of overweight and obesity \(^{30,31}\). Further, food insecurity has been associated with several diet-related conditions, including diabetes and hypertension.

Risk Factors for Kidney Disease

Data over the recent decades have linked a host of genetic, environmental, socio-demographic and clinical factors to risk of kidney disease. The population burden of kidney disease is known to correlate with socially-defined factors in most societies across the world. This is better documented in high-income countries, where racial/ethnic minority groups and people of low socioeconomic status carry a high burden of disease. Extensive data has demonstrated that racial and ethnic minorities (e.g. African-Americans in the United States, Aboriginal groups in Canada and Australia, Indo-Asians in the United Kingdom, and others) suffer disproportionately from advanced and progressive kidney disease \(^{10-12}\). The associations of socioeconomic status and risk of progressive CKD and eventual kidney failure have also been well described with lower socioeconomic status individuals bearing the greatest burden \(^{13,14}\).

Recent works have associated apolipoprotein L1 (APOL1) risk variants \(^{15,16}\) with increased kidney disease burden among persons with African ancestry. In Central America and Southeastern Mexico, Mesoamerican nephropathy [also referred to as CKD of unknown causes (CKDu)] has emerged as an important etiology of kidney disease. While multiple exposures have been studied for their potential role in CKDu, recurrent dehydration and heat stress are common denominators in most cases \(^{17}\). Other, perhaps more readily modifiable, risk factors for kidney disease and CKD progression that disproportionately impact socially disadvantaged groups have also been identified including disparate rates and poor control of clinical risk factors such as diabetes and hypertension, as well as lifestyle behaviors.

Diabetes is the leading cause of advanced kidney disease worldwide \(^{18}\). In 2016, 1 in 11 adults worldwide had diabetes and greater than 80% were living in low- and middle-income countries \(^{19}\) where resources for optimal care are limited. Hypertension is also estimated to affect 1 billion individuals worldwide \(^{20}\), and is the second leading attributed cause of CKD \(^{18}\). Hypertension control is important for slowing CKD progression as well as decreasing mortality risk among persons with or without CKD. Hypertension is present in over 90% of individuals with advanced kidney disease \(^{18}\), yet racial/ethnic minorities and low-income persons with CKD living in high-income countries have poorer blood pressure control than their more socially advantaged counterparts \(^{21}\).
public policies and financial status of individual countries. For example, gross domestic product is correlated with lower dialysis-to-transplantation ratios, suggesting greater rates of kidney transplantation in more financially solvent nations. In several high-income countries, universal health care is provided by the government and includes CKD and ESRD care. In others, such as the United States, ESRD care is publicly financed for citizens, however, optimal treatment of CKD and its risk factors may not be accessible for persons lacking health insurance, and regular care of undocumented immigrants with kidney disease is not covered [37]. In low- and lower-middle-income countries, neither CKD nor ESRD care may be publicly financed and CKD prevention efforts are often limited. In several such countries, collaborations between public and private sectors have emerged to provide funding for RRT. For example, in Karachi, Pakistan, a program of dialysis and kidney transplantation through joint community and government funding has existed for more than 25 years [38].

In many settings, individuals with advanced CKD who have no or limited public or private sector funding for care shoulder substantial financial burden. A systematic review of 260 studies including patients from 30 countries identified significant challenges including: fragmented care of indeterminate duration, reliance on emergency care, and fear of catastrophic life events because of diminished financial capacity to withstand them [39]. Another study, conducted in Mexico, found that patients and families were burdened with having to navigate multiple health and social care structures, negotiate treatments and costs, finance their health care, and manage health information [40]. Challenges may be even greater for families of children with ESRD, as many regions lack qualified pediatric care centers.

ORGANIZATION AND STRUCTURES FOR KIDNEY DISEASE CARE
The lack of recognition and therefore absence of a global action plan for kidney disease partly explains the substantial variation in structures and capacity for kidney care around the globe. This has resulted in variations in government priorities, healthcare budgets, care structures, and human resource availability [41]. Effective and sustainable advocacy efforts are needed at global, regional, and national levels to get kidney disease recognized and placed on the global policy agenda.

In 2017, the ISN collected data on country-level capacity for kidney care delivery using a survey, the Global Kidney Health Atlas (GKHA) [4], which aligned with the WHO’s building blocks of a health system. The GKHA highlights limited awareness of kidney disease and its consequences and persistent inequities in resources required to tackle the burden of kidney disease across the globe. For example, CKD was recognized as a health care priority by government in only 36% of countries that participated in this survey. The priority was inversely related to income level: CKD was a health care priority in more than half of low- and lower-middle-income countries, but in less than 30% of upper-middle- and high-income countries.

On capacity and resources for kidney care, many countries still lack access to basic diagnostics, a trained nephrology workforce, universal access to primary health care, and RRT technologies. Low- and lower-middle-income countries, especially in Africa, had limited services for the diagnosis, management, and monitoring of CKD at the primary care level, with only 12% having serum creatinine measurement including estimated glomerular filtration rate. Twenty-nine percent of low-income countries had access to qualitative urinalysis using urine test strips; however, no low-income country had access to urine albumin-to-creatinine ratio or urine protein-to-creatinine ratio measurements at the primary care level. Across all world countries, availability of services at the secondary/tertiary care level was considerably higher than at the primary care level (Figures 1A and 1B) [4,42].

Renal Replacement Therapies
The distribution of RRT technologies varied widely. On the surface, all countries reported having chronic hemodialysis services, and more than 90% of countries reported having acute hemodialysis. However, access to and distribution of RRT across countries and regions was highly inequitable, often requiring prohibitive out-of-pocket expenditure, particularly in low-income regions. For instance, more than 90% of upper-middle- and high-income countries reported having chronic peritoneal dialysis services, whereas these services were available in 64% and 35% of low- and lower-middle-income countries, respectively. In comparison, acute peritoneal dialysis
had the lowest availability across all countries. More than 90% of upper-middle- and high-income countries reported having kidney transplant services, with more than 85% of these countries reporting both living and deceased donors as the organ source. As expected, low-income countries had the lowest availability of kidney transplant services, with only 12% reporting availability, and live donors as the only source.

**Figure 1A: Health Care Services for Identification and Management of Chronic Kidney Disease by Country Income Level: Primary Care**

HbA1C: Glycated hemoglobin; eGFR: estimated glomerular filtration rate; UACR: urine albumin-to-creatinine ratio; UPCR: urine protein-to-creatinine ratio. Primary care = Basic health facilities at community levels (clinics, dispensaries, small local hospitals).

Data source:
- Global Kidney Health Atlas (2016)
Considerable international variation was also noted in the distribution of the kidney care workforce, particularly nephrologists. The lowest density (<5 nephrologists per million population) was very common in low-income countries, whereas the highest density (>15 nephrologists per million population) was reported mainly in high-income countries (Figure 2) [4,43,44]. Most countries reported nephrologists as primarily responsible for both CKD and AKI care. Primary care physicians (PCPs) had more responsibility for CKD care than for AKI care, as

Data source:
- Global Kidney Health Atlas (2016)

**Workforce for Kidney Care**

HbA1C: Glycated hemoglobin; eGFR: estimated glomerular filtration rate; UACR: urine albumin-to-creatine ratio; UPCR: urine protein-to-creatine ratio. Secondary care/Specialty care = Health facilities at a level higher than primary care (clinics, hospitals, academic centers).
hospitals. However, only 45% of low-income countries reported that intensive care specialists were primarily responsible for AKI, compared to 90% of high-income countries; this discrepancy may be due to

Figure 2: Nephrologist Availability (density per million population) compared to Physician, Nursing, and Pharmaceutical Personnel Availability by Country Income Level*

* Logarithmic scale used for x-axis [log(x+1)] due to the large range in provider’s density
Pharmaceutical personnel include: pharmacists, pharmaceutical assistants, pharmaceutical technicians. Nursing and midwifery personnel include: professional nurses, professional midwives, auxiliary nurses, auxiliary midwives, enrolled nurses, enrolled midwives and related occupations such as dental nurses.

Data source:
- Physician, nursing and pharmaceutical personnel: WHO Global Health Observatory Indicator (most recent available year)

64% of countries reported PCPs primarily responsible for CKD and 35% for AKI. Intensive care specialists were primarily responsible for AKI in 75% of countries, likely because AKI is typically treated in hospitals. However, only 45% of low-income countries reported that intensive care specialists were primarily responsible for AKI, compared to 90% of high-income countries; this discrepancy may be due
Burden, Access and Disparities in Kidney Disease

to a general shortage of intensive care specialists in low-income countries.

The appropriate number of nephrologists in a country depends on many factors, including need, priority, and resources, and as such there is no global standard with respect to nephrologist density. Regardless, the demonstrated low density in low-income countries calls for concern as nephrologists are essential to provide leadership in kidney disease care, and a lack of nephrologists may result in adverse consequences for policy and practice. But quite encouragingly, the number of nephrologists and nephropathologists is rising in low- and lower-middle-income countries, in part thanks to fellowship programs supported by international nephrology organizations [45]. It is important to note that the role of a nephrologist may differ depending on how the health care system is structured. The density statistic merely represents the number of nephrologists per million population and provides no indication of the adequacy to meet the needs of the population or quality of care, which depends on volume of patients with kidney disease and other workforce support (for example, availability of multidisciplinary teams).

For other care providers essential for kidney care, there were international variations in distribution (availability and adequacy). Overall, provider shortages were highest for renal pathologists (86% of countries reported a shortage), vascular access coordinators (81%), and dietitians (78%), and the shortages were more common in low-income countries. Few countries (35%) reported a shortage in laboratory technicians. This information highlights significant inter- and intra-regional variability in the current capacity for kidney care across the world. Important gaps in awareness, services, workforce, and capacity for optimal care delivery were identified in many countries and regions [4]. The findings have implications for policy development towards establishment of robust kidney care programs, particularly for low- and lower-middle-income countries [47]. This has therefore provided a baseline understanding of where countries and regions stand with respect to several domains of the health system, thus allowing the monitoring of progress through the implementation of various strategies at achieving equitable and quality care for the many patients with kidney disease across the globe.

How could this information be used to mitigate existing barriers to kidney care? First, basic infrastructure for services must be strengthened at the primary care level for early detection and management of AKI and CKD across all countries [46]. Second, whilst optimal kidney care should obviously emphasize prevention to reduce adverse consequences of kidney disease at the population level, countries (particularly low- and lower-middle-income countries) should be supported at the same time to adopt more pragmatic approaches in providing RRT. For example, acute peritoneal dialysis could be an attractive modality for AKI, as this is as effective as hemodialysis, requires far less infrastructure, and can be performed with solutions and catheters adapted to local resources [47]. Third, kidney transplantation should be encouraged through increased awareness among the public and political leaders across countries, as this is the clinically optimal modality of RRT and it is also cost-effective, provided that costs of the surgery and long-term medication and follow-up are made sustainable through public (and/or private) funding [48]. Currently, most kidney transplants are conducted in high-income countries in part due to lack of resources and knowledge in low and lower-middle-income countries as well as cultural practices and absence of legal frameworks governing organ donation [48].

CONCLUSION
Socially disadvantaged individuals experience a disproportionate burden of kidney disease worldwide. The provision of and delivery of kidney care varies widely across the world. Achieving universal health coverage worldwide by 2030 is one of the WHO Sustainable Development Goals. While universal health coverage may not include all elements of kidney care in all countries (as this is usually a function of political, economic, and cultural factors), understanding what is feasible and important for a country or region with a focus on reducing the burden and consequences of kidney disease would be an important step towards achieving kidney health equity.

Disclosure
All authors have contributed to the manuscript equally. All the authors declared no competing interests.

Acknowledgements
The authors thank the Global Kidney Health Atlas team, M. Lunney, and M.A. Osman.
REFERENCES
17. Ricardo Correa-Rotter, Chapter 22 - Mesoamerican Nephropathy or Chronic Kidney Disease of Unknown Origin, Editor(s): Guillermo Garcia-Garcia, Lawrence Y. Agodoa, Keith C. Norris, Chronic Kidney Disease in Disadvantaged


44. World Health Organization. Global Health Observatory indicator views. [Internet]. Most recent year. [cited 24 July 2018]. Available from: http://apps.who.int/gho/data/node.imr#ndx-P


